Display options
Share it on

iScience. 2021 Dec 04;25(1):103549. doi: 10.1016/j.isci.2021.103549. eCollection 2022 Jan 21.

[No title available]


Maria Jimenez Ramos, Lucia Bandiera, Filippo Menolascina, Jonathan Andrew Fallowfield


  1. Centre for Inflammation Research, The University of Edinburgh, The Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK.
  2. Institute for Bioengineering, The University of Edinburgh, Edinburgh EH9 3BF, UK.
  3. Synthsys - Centre for Synthetic and Systems Biology, The University of Edinburgh, Edinburgh EH9 3BF, UK.

PMID: 34977507 PMCID: PMC8689151 DOI: 10.1016/j.isci.2021.103549


Non-alcoholic fatty liver disease (NAFLD) represents a global healthcare challenge, affecting 1 in 4 adults, and death rates are predicted to rise inexorably. The progressive form of NAFLD, non-alcoholic steatohepatitis (NASH), can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. However, no medical treatments are licensed for NAFLD-NASH. Identifying efficacious therapies has been hindered by the complexity of disease pathogenesis, a paucity of predictive preclinical models and inadequate validation of pharmacological targets in humans. The development of clinically relevant

© 2021 The Author(s).

Keywords: Bioengineering; Cell biology; Cellular physiology

Conflict of interest statement

JA Fallowfield has served as a consultant or advisory board member for Redx Pharma, Novartis, Ferring Pharmaceuticals, Macrophage Pharma, Galecto Biotech, Caldan Therapeutics, Cypralis Ltd, Rallybio,

Publication Types